NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No. 8,846,893, covering novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
Specifically, the patented technology describes delivery of nucleic acids to specific cells in order to direct gene therapy to the sites where it would be most useful. It involves use of a complex of a cell-specific antibody uniquely capable of being linked to a nucleic acid sequence selected for its ability to interfere with the disease process or to correct a genetic deficiency. Apart from its therapeutic applications, the technology can also be applied to research studies of virus infections and genetic diseases.
Help employers find you! Check out all the jobs and post your resume.
